Quick Answer
Greenwich LifeSciences, Inc. reported Cash and Equivalents of $4.09 million for fiscal year 2024.
Greenwich LifeSciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $4.09M | -41.5% |
| 2023 | $6.99M | -48.1% |
| 2022 | $13.47M | -50.5% |
| 2021 | $27.20M | -5.1% |
| 2020 | $28.66M | +419217.8% |
| 2019 | $6.8K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.81M | -34.6% | +21.8% |
| June 30, 2025 | $3.13M | -56.7% | +13.6% |
| March 31, 2025 | $2.75M | -50.1% | -32.8% |
| December 31, 2024 | $4.09M | -41.5% | -29.7% |
| September 30, 2024 | $5.82M | -36.3% | -19.4% |
| June 30, 2024 | $7.22M | -34.0% | +31.2% |
| March 31, 2024 | $5.51M | -53.8% | -21.2% |
| December 31, 2023 | $6.99M | -48.1% | -23.6% |
- Greenwich LifeSciences, Inc. showed a decrease of -41.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2024 period, Greenwich LifeSciences, Inc.’s cash and equivalents has grown by 59768.2% (from $6.8 thousand to $4.09 million).
- The most recent figure is from Greenwich LifeSciences, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: